Testing whether TRC102 combined with temozolomide is effective in patients with brain cancer

What we are studying

The purpose of this study is to test any good and bad effects of the study called TRC102 when combined with a standard treatment for brain cancer, temozolomide.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Progressive or recurrent glioblastoma

What is involved

  • Study participants will take TRC102 my mouth once a day for 5 days every 28 days. Study participants will also take temozolomide once a day for 5 days every 28 days. Study participants will be asked to return to clinic every 28 days.


Parking for study all study related visits will be validated

Contact Information

Study Coordinator
Jill Weber Pfefferkorn

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.